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Introduction
Circumcision is the oldest planned operative procedure in the history of the human
civilization but there continues to be a lack of consensus and strong opposing views on
whether universal neonatal circumcision should be adopted as a public health measure.
The recent American Academy of Pediatrics (AAP) guideline on male circumcision
(MC), reversed its prior stand stating that the “ health benefits of newborn male
circumcision outweigh the risks” and justify access to the procedure if the parents so
choose [1]. This recommendation was primarily based on the impressive results from
African trials demonstrating the protective effect of MC against Human
Immunodeficiency Virus (HIV) and sexually transmitted infections (STI).
A review of the literature on MC shows evidence of a vehement debate, often clouded by
strong personal biases and lack of high quality evidence. Creation of a guideline specific
to the need of Canadian infant males is therefore difficult given the level of evidence
provided for each potential benefit, the lack of data directly applicable to the Canadian
population, the inability to quantify the true complication rate of routine circumcisions
accurately, uncertainty about the health benefits of a circumcision compared with other
health interventions, the ethical issues and acceptability of a surgical procedure done by
parental consent for future benefits, and the costs of training and implementation of any
universal neonatal circumcision policy in Canada.
Acceptance and trends of neonatal circumcision
Neonatal circumcision rates are declining across several countries including Canada and
this may be a reflection of changing demographic patterns and parental beliefs. The
Provincial Ministries of Health in Canada indicate circumcision rates of 51-67% in 1970.
In 2009, the Public Health Agency of Canada reported an overall Canadian circumcision
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rate of 31.9% for 2006-2007 [Public Health Agency of Canada, 2009]. This varied across
the provinces with the rate being highest in Alberta (44.3%) and lowest in Nova Scotia
(6.8%) (www.circinfo.net).
A Centers for Disease Control and Prevention (CDC) report showed a decreasing
trend in US circumcision rates from 1999-2000 till 2008-2010 from 60% to 55% of
newborn males [2]. In the UK between 1997-2004, circumcision rates declined from
2.6/1000 boys/year to 2.1/1000 boys/year [3]. However, a more recent study from the US
using the Nationwide Inpatient Sample noted an increasing trend of neonatal
circumcisions from 48% in 1988-1991 to 61% in 1997-2000, reflecting an increase of
6.8% on average every year [4].
A survey of prospective parents in the US was assessed to obtain parental views
of circumcision analyzing the effect of the AAP 1999 circumcision guideline and recent
HIV and Human Papilloma Virus (HPV) trials [5]. Individuals with previous circumcised
sons, those born in the US and those who discussed circumcision with their partner were
more likely to request circumcision. There was no change in support after reading
information on recent HIV/HPV trials from Africa. A similar survey in Canada indicated
that circumcision status of the father significantly influences the child’s circumcision [6].
This study indicates that initial parental views rather than new evidence may continue to
be the strongest determinant for neonatal circumcision.
Aims of the review
The aim of this guideline is to present the current evidence on the benefits of
circumcision, the optimal anesthesia/analgesia requirements of neonatal circumcision, the
possible complications of circumcision and its effect on sexual function and sensation
and the care of a normal foreskin in early childhood. This guideline is directed towards
pediatric care- givers who routinely examine and follow male infants, physicians who
provide neonatal circumcision services and pediatric urologists and general surgeons. The
current guideline is written with the purpose of being applicable to the Canadian
population and health care system. The evidence presented is classified according to the
Oxford system of evidence-based medicine [7].
The current guideline attempts to answer the following questions:
1. Do the potential benefits of neonatal circumcision justify performing
universal neonatal circumcision in Canada?
2. For an individual patient and parent, what are the benefits and risks of a
neonatal circumcision and how reliable and applicable is the evidence
currently available?
3. What should be the prescribed routine foreskin care in infants, indications
for medically indicated circumcision and management of physiological
phimosis?
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Methods
Systematic literature searches were conducted in MEDLINE including Pre-MEDLINE
EMBASE, BIOSIS Previews®, Web of Science® – with Conference Proceedings,
and the Cochrane Central Register of Controlled Trials electronic bibliographic databases
and were restricted to either adult or pediatric studies (</> 18 years) (2002 to March
2013). All searches were restricted to studies published in English language only.
The search queries were developed using combination of subject headings and
free-text terms such as circumcision, circumcision male, uncircumcised, male sexual
dysfunction, sexual dysfunction physiological, sexual dysfunctions psychological,
erectile dysfunction, sexual problems, sexual arousal disorder, ejaculation dysfunction,
sexuality, prostatic neoplasms, prostate cancer, prostate tumor, penile neoplasms, penile
cancer, urinary tract infections, phimosis, HIV infections, HIV, human
immunodeficiency virus, HPV infections, STI’s, using variant spellings and endings. For
all searches, editorials, news and letters were excluded. The bibliographies of all relevant
retrieved articles and reviews were also examined to identify further relevant articles.
A total of 2674 records were identified and after removing duplicate records and
excluding non-relevant studies, 229 studies were identified for detailed analysis and
included in this analysis.
Care of the normal foreskin in childhood and management of physiological phimosis
Natural history of the foreskin
The prepuce arises from the coronal margin by a combination of folding and epithelial
outgrowth and has an outer and inner layer separated by Dartos fascia. At birth, the inner
foreskin is usually fused to the glans penis and should not be forcibly retracted unless it is
possible to retract it with gentle traction. Initial examination of the newborn with a
normal prepuce without any ventral deficiency or dorsal hood is usually (except in a baby
with a megameatus intact prepuce variant of hypospadias) a reliable indicator that the
urethral meatus is in a normal location and rules out significant hypospadias.
The collection of smegma (a white exudate of skin cells and keratin) separating
the prepuce from the glans and repeated reflex erections are the primary mechanisms
which lead to resolution of physiologic adhesions over time. This process is usually
complete by 3 years of age in 90% of the boys, though this study is a reflection of the
poor current data in this regard [8]. In a more recent study from Taiwan the incidence of
non- retractable physiological phimosis was 50% in grade 1 boys and decreased to 35%
in grade 4 and 8% in grade 7 boys [9].
When does physiological phimosis require treatment?
In the absence of clinical findings of scarring suggesting pathological phimosis, and
history of recurrent urinary tract infections (UTI’s) or balano-posthitis, no intervention is
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required for physiological phimosis. Ballooning of the foreskin during voiding is not
associated with obstructed voiding and is not an indication for circumcision [10]. Active
retraction has the potential to cause micro-tears and lead to scarring and subsequently a
true phimosis. Therefore, normal foreskin care in early childhood only starts once the
foreskin is retractable and this will happen at varying ages. Once retractable, the child can
be taught to gently retract and clean during bathing with normal soap and water.
Indications for urological consultation in this age group include suspicion of true
phimosis with evident scarring of the preputial ring (Fig 1), genital Lichen sclerosis (Fig
2), recurrent episodes of balanitis (Fig 3) or UTI [4]. If the foreskin is not open by 8-10
years of age, there may be an indication for steroid therapy and gentle retraction, though
there is no prescribed, evidence proven age cut-off for this process.
Treatment of physiological phimosis
Several observational studies and randomized trials have investigated the role of topical
steroids and preputial stretching in resolving physiologic phimosis. The key to success
with these protocols lies in differentiating physiologic and true phimosis, active
counseling and patient selection. Topical steroid aids by thinning the preputial skin and
obliterating the stratum corneum, which then allows gentle retraction over time.
Level 1 evidence
Letendre conducted a randomized double- blind study comparing a 2- month treatment
course of emollient cream versus 0.1% triamcinolone in boys 3-12 years of age [12]. At 4
months, 76% of those on triamcinolone cream responded as compared to 39% in the
placebo group (p=0.008), with no complications. At 1 year follow up; the success rate in
the steroid group had come down to 47%. In another RCT comparing a moderately potent
steroid mometasone to moisturizing cream, the authors found a significantly better
response rate of 88% at 8 weeks compared to 52% in the placebo group [13]. In a
randomized double-blinded placebo controlled study using betamethasone, Lund et al
showed an initial 74% cure rate at 4 weeks follow up [14]. At 18 months, 14% showed a
relapse, but none required a circumcision. A lower success rate of 52% was noted by
Nobre et al in an RCT from Brazil using 0.2% betamethasone-hyaluronidase cream in
boys 3-10 years of age [15].
Success rates did not vary by steroid potency as shown by similar foreskin
retraction rates using clobetasone (moderately potent steroid, success rate 77%)
compared to betamethasone (highly potent steroid, success rate 81%) [16]. Side effects
are rare and there was no suppression of the hypothalamic-pituitary-adrenal axis provided
treatment is not prolonged beyond 8 weeks for each course [17].
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Level 2‒4 evidence
Zavras et al conducted a prospective study using a mildly potent steroid, fluticasone
propionate (0.05%), to achieve a 91% success rate in 1185 boys referred with a diagnosis
of phimosis [18]. Long –term success is maintained in over 75% of the boys following
initial success with steroid therapy [19, 20]. Ku et al noted that success rates were higher
in boys < 3 years of age (92%) compared to those ≥ 3 years (70%), which may reflect
compliance or a higher likelihood of pathological phimosis in the older group [21].
Ashfield et al showed a reverse trend of better success rate in older boys, though the
result was not found to be statistically significant at any age cut off [22]. Elmore et al
showed that topical steroids as an alternative to circumcision are equally effective (74%)
and safe in infants presenting with genitourinary abnormalities and UTI’s [23].
Recommendations (care of the normal foreskin and physiological phimosis):
1. Neonatal examination of the foreskin and urethral meatus should be part
of routine clinical assessment of all newborn boys. Continued
examination of the foreskin without forcible retraction is recommended
during yearly physical examinations to rule out pathological phimosis
and document natural preputial retraction (Level 5, Grade D).
2. Persistent physiological phimosis in an asymptomatic child should not be
an indication for circumcision [Level 5, Grade D].
3. Physiological phimosis requires treatment if associated with true
balanoposthitis or recurrent UTI’s [Level 5, Grade D]
4. Topical steroids are the first line of treatment for persistent physiological
phimosis requiring treatment with good success rates and low risk of
complications (Level 1b/2b, Grade A).
5. Moderately- low potency steroid (triamcinolone, clobetasone,
hydrocortisone, mometasone) may have similar success compared to a
highly potent steroid (betamethasone) (Level 2b, Grade B).
6. Patient selection to ensure compliance, demonstrating the technique of
gentle retraction of the foreskin and continued retraction after initial
success is important to achieve continued success to topical steroid
therapy (Level 5 Grade D).
7. Recurrence of physiological phimosis is common and normally responds
to another course of topical steroids (Level 2b/3 Grade C).
Circumcision and risk of urinary tract infections
Prior evidence indicates that neonatal circumcision decreases the risk of urinary tract
infections (UTI). The current debate centers on the magnitude of this effect, the overall
effect given the low prevalence of male UTI, the lack of high level evidence and the need
for a surgical procedure to prevent this risk. The role of circumcision in preventing UTI’s
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must be studied in 2 distinct subgroups: males with normal urinary tracts and those with
recurrent UTI’s or urological conditions predisposing to UTI like vesicoureteric reflux,
posterior urethral valves, neurogenic bladders and primary megaureters.
Childhood UTI epidemiology
Prior data suggest that in boys without predisposing urological conditions, the estimated
incidence of UTI in the first 10 years of life varies between 1 to 2% [24, 25]. The
prevalence rate of UTI in symptomatic children is higher. In a meta- analysis of 18
studies, Shaikh et al estimated that in all febrile infants (males and females 0-24 months),
the prevalence of UTI was 7 % (95% CI 5.5-8.4%) [26]. In older symptomatic children
(2-19 years) the prevalence was 7.8% (95% CI 6.6-8.9%). Males under 3 months of age
had the highest prevalence of UTI (8.7%, 95% CI 5.4-11.9). There was evidence of
significant heterogeneity but no publication bias and bagged specimens were included in
some studies.
Biological plausibility for the role of circumcision in UTI prevention
Circumcision prevents UTI by reducing periurethral bacterial colonization secondary to
reduced adherence of bacteria to keratinized surfaces and by removing the growth
promoting moist preputial environment [27-29]. Foreskin colonization with potential
pathogenic bacteria occurs early and leads to an increase in protective Langerhans cells.
[30]. In a case control study, circumcision decreased the bacterial colonization of the
glans penis for uropathogenic bacteria when compared to boys with an intact foreskin and
this effect persisted in older boys [31]. Studies have shown E. coli strains causing UTI in
uncircumcised male infants resemble urosepsis strains isolated in adults [32]. In addition,
data from the human immunodeficiency virus type 1 (HIV) trial in Uganda showed a
decreased prevalence and load of 12 specific anaerobic bacteria following circumcision
[27].
Boys with normal urinary tracts
Level 2 evidence
In a meta- analysis, among febrile male infants less than 3 months of age, the prevalence
of UTI was 10 times higher in uncircumcised males (20.1% 95% CI: 16.8-23.4) than
circumcised males (2.4% 95% CI: 1.4-3.5) [26]. This difference decreased in the 6-12month group (7.3% and 0.3%) and there was no data available beyond infancy.
Translated to likelihood ratios (LR), the uncircumcised male infant (3-24 months old) has
a UTI LR of 2.8 versus 0.33 for circumcised males [33]. The risk increases if this infant
is of non- black race. Singh-Grewal performed a meta-analysis of 12 published studies (1
RCT, 4 cohort, 7 case-control) on 402,908 children published till 2002 and assuming a
1% risk of UTI calculated the number of circumcisions required to prevent 1 UTI as 111
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[34]. The quality of the included studies was poor, with variable UTI definitions, bagged
specimens in at least 6 studies and potential differential misclassification as 3/4 cohort
studies were unable to account for circumcisions past the neonatal period. The overall
odds ratio (OR) for a UTI in circumcised males compared to uncircumcised males was
0.13 (95% CI, 0.07 to 0.23). The single RCT by Nayir et al included in this analysis,
compared bacteriuria rates between circumcised and uncircumcised boys using bag or
mid stream specimens and showed a non-statistically significant OR of 0.13 in the
circumcised group (95% CI, 0.01 to 2.63) [35].
A systematic review conducted by Morris et al, calculated the lifetime risk of a
UTI to be 32% in uncircumcised males compared to 9% in circumcised males [36]. The
authors suggested a NNT of 4.2 (95% CI 2.2-27) for preventing 1 UTI over a lifetime. A
Cochrane review in 2012 failed to identify any new RCT’s to include in a meta-analysis
[37].
Level 2-4 evidence
Zorc et al conducted a prospective cross sectional study to identify clinical factors
associated with UTI in infants <60 days of age [38]. The overall rate of UTI was 9% and
after multivariable adjustment, being uncircumcised was associated with a higher UTI
risk (OR 10.4; 95% CI 4.7-31.4, p <0.001). According to a large population- based cohort
study conducted in Canada by To et al, the relative risk of UTI requiring hospital
admission in uncircumcised compared to circumcised boys was 3.7 (95% CI, 2.8-4.9) in
the first year of life [39]. The number of circumcisions needed to prevent one admission
for UTI in the first year of life was 195. In another well- conducted case control study
from Australia which included children with urological abnormalities, Craig et al showed
that the protective effects of circumcision in reducing risk of UTI extended beyond
infancy [40]. In infants, the OR was marginally significant at 0.03 (95% CI 0.06-1.1).
However, the OR for the >1- year group was not statistically significant (OR=0.2, 95%
CI 0.01-3.7).
The rate of asymptomatic positive urine cultures (bag specimens confirmed with
suprapubic aspiration) was significantly lower in a study by Simforoosh et al [41]. None
of the 3000 circumcised children followed up to 15-months age had a positive culture
while 2% of the 1000 uncircumcised males had a positive culture. Interestingly, several
studies from Israel, where all males undergo a ritual neonatal circumcision, showed a
high incidence of post-circumcision UTI [42, 43].
Boys with abnormal urinary tract
In urological conditions like high grade VUR, posterior urethral valves, primary
megaureters the risk of UTI is higher.
Vesicouretric reflux: In a prospective cohort study, Alsaywid et al noted a lower
non- significant incidence of new defects on DMSA scans in circumcised males with
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grade IV-V VUR as compared to uncircumcised boys (5.25 versus 10.2%) [44].
However, 3 of the 4 boys in the circumcised group with new DMSA defects, did not get
breakthrough UTI’s. Circumcision was more effective than antibiotic prophylaxis alone
or anti-reflux surgery in preventing breakthrough UTI (OR 0.9). In contrast after surgical
correction of VUR, a concomitant circumcision did not decrease the risk of postoperative UTI [45]. In a small RCT conducted on children < 3 years with low grade VUR
(Grade 1-3), randomized to antibiotic prophylaxis and prophylaxis plus circumcision
groups, the authors noted significantly lower positive peri-urethral cultures in the
circumcised group up till 9 months of follow up following which results equalized [46].
The authors also showed a significantly lower positive culture rate by urethral
catheterization in the circumcised group but did not comment these patients were
symptomatic.
Posterior urethral valves: Mukherjee et al showed in a retrospective cross
sectional study, that circumcision in boys with posterior urethral valves significantly
reduces the incidence of UTI beyond infancy by 83% [47]. Given that their cohort had a
very high incidence of UTI, the NNT to prevent 1 UTI was 1 in boys with valves.
UPJ obstruction and antenatal hydronephrosis: In a recent prospective study on infants
with antenatally detected hydronephrosis, uncircumcised boys (adjusted OR 3.63, 95%
CI: 1.2-11.2) and females had a significantly higher risk of febrile UTI compared to
circumcised males [48].
Roth et al did not demonstrate a protective effect of circumcision in children with
grade 3-4 hydronephrosis secondary to UPJ obstruction or obstructive megaureters in a
retrospective cohort study [49]. Though unable to show statistical significance, the UTI
rate was 0 in circumcised males as opposed to 8.3% in uncircumcised males. In addition,
there is indirect evidence of the protective effect of circumcision in this population when
comparing this study (63% circumcised) which had a 4.3% UTI rate with a similar cohort
presented in a study by Song et al, which had a higher 36% UTI rate (0% circumcised)
[50].
It is unclear whether medical treatment of physiological phimosis or antibiotic
prophylaxis can prevent UTI’s as effectively as circumcision in this subset of males.
Urine specimen collection methodology is an issue and a recent study demonstrated that
even catheterized specimens in uncircumcised boys could be contaminated [51]. Studies
measuring the incidence of UTI’s are intrinsically more difficult to interpret as most
measure number of UTI episodes as opposed to number of children with UTI. Assuming
a 1-2% circumcision complication rate and a 1% UTI risk in normal infants, universal
neonatal circumcision cannot be justified based on a number needed to treat (NNT) of
111 [34]. Even if we accept a lower complication rate of 0.2% and a 2% UTI risk, given
the effectiveness of UTI treatment, 6 UTI’s will be prevented at the expense of 1
circumcision complication. This equation changes in the favor of a circumcision in those
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with recurrent UTI (assuming a risk of 10%, the NNT is 11) and boys with urological
abnormalities (even assuming a inflated risk of UTI with VUR being 30%, the NNT is 4)
[34].
Recommendations (MC and UTI prevention):
1. Neonatal circumcision decreases the risk of UTI (Level 2a).
2. The risk of UTI is low in infant males and decreases further beyond
infancy (Level 2b-4).
3. There is paucity of level-1 evidence to justify recommending universal
circumcision to prevent UTI’s in normal males.
4. A stronger effect of neonatal circumcision in preventing UTI’s in boys
with urological abnormalities has been demonstrated and therefore it is
recommended that a discussion with the parents is advisable for this
subgroup of neonates (Level 3-4 Grade C).
Circumcision and risk of sexually transmitted infections
A decreased risk of HIV and other STI’s is the primary argument driving a change in
risk-benefit assessment of male circumcision. The other benefits of MC are
overshadowed to a large extent by its effect on HIV and STI’s and therefore data in
relation to these benefits must be scrutinized carefully to obtain evidence- based
recommendations.
1. Circumcision and HIV prevention
Epidemiology of HIV infections
A recent Public Health Agency of Canada report estimated a HIV prevalence rate of 208
per 100,000 population, with an 11.4% increase compared to 2008 estimates [52]. Men
who have sex with men (MSM) accounted for 47% of prevalent infections followed by
intra-venous drug users (17%) and heterosexual individuals (17.6%).
Based on RCT’s conducted in HIV high prevalence sub-Saharan Africa, there is
clear Level 1 evidence that male circumcision reduces the risk of HIV infection in
heterosexual men, in that region of the world [53-55]. In 2007, the WHO and UNAIDS
recommended MC, regardless of HIV serostatus, as an additional intervention in
countries with predominant heterosexually acquired HIV infection, where HIV is
prevalent and circumcision rates are low [56]. Circumcision should not replace promotion
of the “ABC” (Abstinence, Behavior change and correct and consistent Condom use)
strategy or value of voluntary counseling and testing and care services for STI’s. The
CDC convened a Consultation on Public Health Issues Regarding Male Circumcision in
the United States For Prevention of HIV Infection in 2007 and put forward the following
key proposals [57]:
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1. With respect to HIV prevention, MC is one of several partially effective riskreduction alternatives for heterosexual men that should be used in
combination with other measures.
2. There is no need or equipoise to conduct a US trial of MC for HIV prevention
among men who have sex with women.
3. There is not enough evidence to make a recommendation for MC for MSM to
prevent HIV infection and there may be equipoise to conduct an efficacy trial
for this population.
4. For newborns, medical benefits outweigh risks and the benefits and risks
should be explained to parents.
Role of prepuce in HIV infection
The protective effect of circumcision against HIV infection has been attributed to several
factors. Microabrasions during intercourse may provide easier access to the virus and the
likelihood of such coital trauma is higher in those uncircumcised [58]. The inner foreskin
mucosa has a higher density of Langerhans cells for which HIV-1 demonstrates specific
tropism in in-vitro studies [59]. Circumcision removes a majority of foreskin Langerhan
cells. Pro-inflammatory anaerobes, which are supported by the anoxic microenvironment
of the intact foreskin, also contribute to viral survival [60]. The lack of keratinization
especially of the inner foreskin compared to a circumcised penis may also aid HIV
infection [61]. In a sub analysis in the control group of the Ugandan RCT, foreskin
surface area was predictive of the risk of HIV acquisition [62]. Men with the largest
foreskin surface area had a 2 times higher incidence rate compared to those with the
lowest quartile surface area.
In addition, higher rates of STI, such as herpes simplex virus -2 (HSV-2) and
genital ulcer disease (GUD), increases susceptibility to HIV infection and circumcision
may decrease HIV risk by these intermediate factors but this relationship is complex and
bidirectional [63- 66].
Female to male HIV transmission
Observational studies
Following the first observational study in 1986 suggesting a decreased risk of HIV in
circumcised men, several studies and a meta-analysis of 15 observational studies
conducted in 2000, supported a protective effect of circumcision against HIV infection
(adjusted RR 0.42, 95% CI 0.34-0.54%) [67, 68]. More recently, Warner et al conducted
a cross sectional study among heterosexual African American men and analyzed the
protective effects of MC in a group of men with known HIV exposure [69]. Circumcision
was associated with a 51% reduction in HIV prevalence among the 394 visits by men
who were exposed to HIV positive female partners (adjusted PRR 0.49, 95% CI 0.26-
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0.93). In contrast, when the HIV exposure was unknown, circumcision status was not
protective (adjusted PRR 1.00, 95% CI 0.86-1.15). A global epidemiological study in 118
countries concluded that circumcision was associated with a lower HIV rates,
independent of religion [70]. However, for non-sub-Saharan countries with a primarily
homosexual or IV drug use modality of HIV transmission, circumcision status was not
associated with a lower risk of HIV infection.
Meta-analysis of HIV RCTs
A Cochrane review of the 3 trials (Table 1) concluded that medical circumcision reduces
the acquisition of HIV by heterosexual men between 38-66% over 2 years, with an
incidence risk ratio of 0.5 (95% CI 0.34- 0.72) at 1 year and 0.46 (95% CI 0.34-0.62) at 2
years follow up in the circumcised group compared to the non-circumcised group [71].
There was no evidence of heterogeneity (I2 0%). With a low assumed control risk of 1%
(10 per 1000 population over a 2-year period), the number needed to treat (NNT) based
on this meta-analysis was 186. The combined per protocol analysis showed a stronger
protective effect (IRR 0.34, 95% CI 0.24-0.47).
The possibility of behavioral disinhibition, leading to unsafe sexual practices, can
potentially offset the protective effect of circumcision and this effect may be dependent
on the timing of circumcision [72]. The South African trial evaluated behavioral aspects
post circumcision and noted a higher mean number of sexual contacts in the circumcised
group compared to the uncircumcised group [55]. The Kenyan trial also showed a
statistically significant difference in the circumcised versus uncircumcised group with
respect to unprotected sexual intercourse and consistent condom usage [53]. The
Ugandan RCT did not find this difference even on long-term follow up [54, 73]. In a
comprehensive analysis of 1309 men enrolled in the Kenyan RCT, Mattson et al
evaluated risk compensation using a self-validated 18 item risk propensity score and
acquisition of other STI’s as a marker of risk behavior [74]. Men in this study were not
clearly informed that MC reduced HIV risk and both groups received intensive
counseling. STI risk was higher in the circumcised group at baseline and incident STI
was higher at 6- month follow up. There was no difference in the risk scores at 6 and 12
month follow up in the 2 groups.
Male to male transmission
According to CDC estimates in 2006, of 56300 new HIV infections in the US, 53% were
in men who have sex with men (MSM) males [75]. Heterosexual transmission was
responsible in 31% cases. Canadian estimates are similar with more than 50% of new
infections occurring in MSM males.
Evidence of an association between circumcision status and HIV infection in men
who have sex with men (MSM) is limited to observational studies, not usually stratified
by receptive and insertive roles. It is believed that men who practice an insertive role
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during anal intercourse would likely benefit from MC while those who perform a
receptive role have little or no protection. Most MSM are likely to be infected through a
receptive rather an insertive role, which would further dilute the effects of MC in this
population. In a Cochrane review by Wiysonge et al, including 21 observational studies
(6 cohort, 14 cross-sectional, 1 case-control; 71,693 participants) were analyzed to assess
the impact of circumcision for preventing HIV infection in MSM males the risk for HIV
acquisition was not associated with MC (OR 0.86, 95% CI 0.7-1.06) [76]. In a subgroup
analysis of men reporting an insertive role, MC was found to be protective (3465
participants; OR 0.27, 95% CI 0.17-0.44). The overall quality of the studies included was
poor with high risk of attrition and detection bias. A previous meta- analysis by Millett et
al in 2008 had also reported a similar non- significant RR of 0.86 amongst all MSM men
and a trend towards lower HIV risk in MSM men who practiced an insertive role (RR
0.70, 95% CI 0.2-2.2) [77].
Londish et al created a mathematical model incorporating circumcision and
seropositioning in the MSM population to predict the reduction in HIV prevalence and
incidence [78]. The authors predicted that in a developed country with 10% HIV
prevalence, with universal circumcision, it would take 20 years to reduce HIV incidence
by 5% compared to pre-intervention levels and prevalence to 9.6%.
Male to female transmission
MC can potentially decrease female partner HIV infection by a direct effect, or indirectly
(over 10-20 years) at the population level by reducing the overall male prevalence.
The Ugandan RCT enrolled 92 couples in the circumcised group and 67 in the control
group to study the direct effects of MC in HIV positive men on female partner HIV status
over a 24 month follow up [79]. This trial was underpowered and terminated early since
recruitment was futile. No evidence of protection was identified (adjusted HR 1.49, 95%
CI 0.62-3.57). A meta-analysis of 7 longitudinal population based studies including the
Ugandan trial did not show any protective effect on female partners of circumcised males
(RR 0.80, 95% CI 0.54-1.19) [80]. There was evidence of between study heterogeneity
with studies showing reverse effects. In a prospective cohort study based on an RCT,
conducted to assess HSV 2 suppression impact on HIV transmission, conducted in Africa
1096 serodiscordant couples were followed for a 18 month period [81]. Circumcision was
associated with a 40% lower risk of HIV transmission to female partners though the
results were not statistically significant (HR 0.62, 95% CI 0.35-1.10).
Conclusions on the benefit of neonatal circumcision in preventing HIV
There are several factors, which have to be considered when adopting findings from
recent evidence as a basis for recommendation of neonatal circumcision in more
developed countries [82-87]. The large sample size, magnitude of the effect, consistent
results across the 3 trials and meta-analyses, and sound statistical methods to address
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confounding factors are the primary strengths of these well conducted trials, which
upholds the internal validity of the results to a large extent barring some concerns. These
concerns include early trial stoppage, inadequate allocation concealment and random
sequence generation, and risk of attrition bias [71, 82]. The primary issue in interpreting
these results relates to external validity of these trials in the Canadian setting.
1. The MC rate in the 3 African trial sites ranged between 10-20% and HIV
prevalence in these countries was between 7-25% (incidence 1.7-1.8% per year).
In contrast, in Canada the MC rate is around 35% and HIV prevalence is much
lower and this would lead to a substantially higher number needed to treat.
2. A difference in the modes of HIV transmission and baseline neonatal
circumcision rates affects the available susceptible population, which will be
protected by MC. Only a small proportion of HIV transmission is due
heterosexual activity and men who have sex with men is a group not protected by
MC.
3. Variations in sexual practices and behavior (including condom usage), and
differences in STI prevalence will also alter the protective effects of MC.
4. Access to health care and earlier detection and treatment for HIV infected males
and HPV vaccination programs may also modify the observed protective effects.
5. Ethical considerations of parental consent and racial/ethnic acceptability further
complicate the issue when implementing universal circumcision programs.
6. Cost benefit analysis compared to alternative preventive strategies, should be
considered and studied in a Canadian context to allow generation of a clear
recommendation [87].
7. The trials were all conducted in sexually active adult men from HIV endemic
areas in Africa who were motivated and interested in a free circumcision. They
also received counseling as part of trial. This will result in overestimation of the
protective effect, different from a more real-world setting.
8. In addition, the long- term effectiveness beyond 2 years follow up is currently
only published for the Ugandan trial [73].
Recommendations (MC and HIV protection):
1. Female to male transmission: There is compelling evidence that MC
reduces the risk of HIV transmission from female partners to male (Level
1 A evidence, Grade A recommendation). The magnitude of the effect is
debatable and cannot be extrapolated to Canada from the African
RCT’s.
2. Male to male transmission: Based on current evidence, MC does not
provide protection for men who have sex with men (Level 2a evidence).
3. Women partners: Based on current evidence, MC is not protective for
female partners (Level 2a-b evidence).

CUAJ – Guideline

Dave et al
Guideline: Foreskin care and neonatal circumcision

4. Universal infant circumcision cannot be recommended to prevent HIV
infection based on current evidence (Grade B).
2. Circumcision and human papilloma virus (HPV) prevention
Human papilloma virus (HPV) is the commonest STI worldwide and of the more than
100 types, about 40 can infect the ano-genital area. In the absence of vaccination, up to
75% of Canadians would have at least one lifetime HPV infection [www.phacaspc.gc.ca]. High- risk oncogenic types like 16 and 18 are implicated in cervical, penile,
vulval, vaginal, anal and some oropharyngeal cancers while low risk non-oncogenic
subtypes like 6 and 11 cause genital warts. The effect of circumcision on HPV is difficult
to interpret as HPV infection can be transient, affect multiple genital areas outside the
foreskin, include several high risk and non-high-risk types and is significantly associated
with other behavioral confounders. In addition, HPV prevalence, incidence, clearance and
viral load are all potential outcomes, which can be studied and have differing health
implications.
HPV in men
Level 1-2 evidence
Auvert et al showed a reduction in the prevalence of urethral high- risk HPV infection
following male circumcision with a prevalence rate ratio of 0.68 (95% CI 0.52-0.89,
p=0.002) in circumcised men as compared to uncircumcised men [88]. Significantly, the
prevalence differences between the 2 groups were not significant for HPV type 16 but
were for HPV type 18.
Six secondary trials analyzed HIV positive and negative men enrolled in the
Ugandan HIV trial with regards to HPV prevalence, acquisition/incidence, clearance and
viral load [89-94]. The first trial investigated the prevalence of HPV in a subgroup of
participants and only included samples from the glans and coronal sulcus, a factor for
possible bias due to differential infection sites in circumcised males [89, 95]. The
adjusted risk ratio for prevalence of high risk HPV at 2 years follow up in the
circumcised group was 0.65 (95% CI 0.46-0.90, p=0.0009) and 0.66 for low risk HPV
genotypes (95% CI 0.49-0.91, p = 0.01). In a subsequent report, the same group showed
that the 1- year penile shaft HPV prevalence after MC was not statistically significant
lower in the circumcised group (adjusted PRR 0.66, 95% CI 0.39-1.12, p= 0.12) [90].
The third trial evaluated HPV acquisition and clearance in HIV negative men using glans
and coronal sulcus samples [91]. The incidence rate of HR-HPV infection was
statistically significant at 1 year (Incidence rate ratio =0.61, 95% CI 0.44-0.85) in the
uncircumcised group but at 2 years follow up the effect was not statistically significant
(IRR=0.64, 95% CI 0.38-1.07). The incidence of type specific HR HPV was statistically
significant for only the 18 and 33 genotypes and not 16. The acquisition of new multiple
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infections was lower in the circumcised group (IRR 0.45, 95% CI 0.28-0.73) compared to
the non-circumcised group. Clearance rates per 100 person years were statistically
significant only for types 39, 51 and 58 and overall clearance rates were higher in the
circumcised group (RR=1.36, 95% CI 1.13-1.63). The fourth study in the Ugandan trial
evaluated HR HPV prevalence, acquisition/incidence and clearance in HIV positive
married men with or without a circumcision [92]. A random sample comprising 22% of
those enrolled was tested at enrollment and at 24 months follows up. MC provided partial
protection with the circumcised group (55% positive) showing lower HR-HPV
prevalence at 24 months (PRR =0.77, 95% CI 0.62-0.97). The incidence rate for one or
more new infections after adjustment was not statistically significant between the
circumcised and non-circumcised group (IRR 0.74, 95% CI 0.54-1.01), however the
proportion of men acquiring multiple new HR-HPV infections was lower in the
circumcised group (IRR 0.40, 95% CI 0.19-0.84). The clearance rate of HPV infections
was not significant different between the 2 arms. In a more recent analysis of 999 men
(HIV positive and negative) from the Ugandan trial, Tobian et al showed an increased
HPV clearance in HIV negative circumcised men (adjusted RR 1.48, 95% CI 0.55-0.89)
and lower incidence of HR-HPV acquisition in HIV positive men (IRR 0.70, 95% CI
1.67-2.44) [93]. The final study evaluated HPV viral load in circumcised and
uncircumcised HPV infected men at 24 months [94]. MC decreased HPV viral load in
circumcised compared to uncircumcised men for new infections acquired after enrollment
but the results were statistically significant for only serotype 16 (p=0.001).
Two meta-analyses were conducted evaluating the effect of MC on HPV [96, 97].
Albero et al in 2012 analyzed data from 14 observational studies and 2 RCTs conducted
between 1971 and 2010 [97]. Accepting heterogeneity in MC reporting status, sites
sampled and methods of detection, in the 1784 participants analyzed with data from the 2
RCT’s, the authors detected a strong inverse association between circumcision and highrisk HPV prevalence with an OR of 0.67 (95% CI 0.54-0.82). The 14 prevalence studies
showed a similar pooled result of overall HPV prevalence (OR 0.57, 95% CI 0.42-0.77).
HPV prevalence remained lower in circumcised men even pooling studies where the
penile shaft or scrotum was sampled. There was no association found between
circumcision and new genital HPV infections or clearance. A previous meta-analysis
conducted by Larke et al till 2010, also showed similar prevalence results (OR 0.57, 95%
CI 0.45-0.71) [96]. This prevalence difference diminished at sites away from the glans
and urethra. There was weak evidence that circumcision was associated with decreased
HPV incidence (RR 0.75, 95% CI 0.57-0.99) or clearance (RR 1.33, 95% CI 0.89-1.98).
Level 2c‒4 evidence
The evidence in regards to effectiveness of circumcision in prevention of HPV
transmission is contradictory when assessing observational and ecological studies.
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Dickson et al followed 450 children from birth in a cohort study conducted in New
Zealand up to 32 years of age with circumcision status reported by mothers at 3 years of
age [98]. Sexual behavior was recorded at 21, 26 and 32 years along with assessment of
socioeconomic and moral-religious emphasis of family. Seropositivity for HPV 16 or 18
at 32 years was lower in the uncircumcised group (Adjusted OR 1.4, 95% CI 0.85-2.2)
but more associated with lifetime number of partners and moral-religious emphasis of the
family of origin. Albero et al reported on 3969 participants from 3 countries followed
over 4 years and used coronal sulcus/glans, penile shaft and scrotal swabs to compare
HPV prevalence in circumcised and non-circumcised males [99]. A multivariable
analysis adjusting for race, marital status, lifetime female sexual partners, female sexual
partners in 3-6 months and male sexual partners in the past 3 months did not find any
association between MC and oncogenic HPV (PR 0.95, 95% CI 0.87-1.03). MC was
significantly associated with a decreased risk of non-oncogenic HPV infection.
Circumcision was associated with a significantly lower HPV 16 seroincidence in MSM
males reporting an insertive role during sex (Adjusted HR 0.47, 95% CI 0.28-0.98,
p=0.043) [100].
HPV in female partners
Two trials conducted on HIV positive and negative men in Uganda analyzed transmission
of HPV to female partners [101, 102]. The implications of reduced HPV infection in
female partner cervical cancer rates are not clearly discernible since there are several
other confounding risk factors.
In the first trial on HIV negative men and their partners, the year- 2 prevalence of
HR-HPV infection in partners was 28% in the circumcised group and 39% in the
uncircumcised group (PRR 0.72, 95% CI 0.60-0.85) [101]. The incidence of any HRHPV infection between 0 and 2 years was also lower in the circumcised group female
partners (IRR 0.77, 95% CI 0.63-0.93). In terms of specific HR genotypes, the results
were specifically not statistically significant for HR-HPV 16 or 18. The clearance rate for
all genotypes was 66% in the circumcised group partners as opposed to 59% in the
uncircumcised partners (p=0.014). This clearance rate was reversed for HPV 16 with the
uncircumcised group having a 74% clearance rate versus 52% in the circumcised group
(RR 0.70, 95% CI 0.54-0.92). In a second trial on female partner HPV infection, Tobian
et al studied the effect of MC in HIV infected men [102]. Circumcision status in male
partners was not associated with lower HR-HPV prevalence in female partners
(PRR=1.07, 95% CI 0.86-1.32, p=0.64) or lower HR-HPV incidence over 2 years
(IRR=1.05, 95% CI 0.77-1.43) or clearance rates (RR=0.96, 95% CI 0.83-1.11).
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Alternative strategies in HPV prevention
The benefit of MC on HPV infection dynamics has to be analyzed in the presence of
complimentary HPV vaccination, protection offered by routine condom usage and other
safe sexual practices. HPV vaccination is currently available and recommended for males
(HPV 4 vaccine, 9-26 years of age), females (HPV 2 or 4 vaccine, 9-13 years and 14-26
years of age) and MSM (HPV 4 vaccine, >9 years of age) with good evidence (Level 1
evidence, Grade A recommendation) of its effectiveness and safety [National Advisory
Committee on Immunization, HPV guideline 2007]. A prospective cohort study showed
that correct and consistent condom usage also decreased risk of HPV transmission by
70% in young newly sexually active women [103].
Recommendations (MC and HPV infections)
1. HPV prevalence in men: Current evidence suggests a modest decrease in
HPV prevalence in the glans and coronal sulcus up to 2 years following
MC. (Level 1b evidence). The protective effect is partial, does not cover
all high- risk types and is weaker further away from the glans and
coronal sulcus. It is not clear whether this effect will persist into
adulthood following neonatal circumcision.
2. HPV clearance in men: There is no evidence (except a single RCT on HIV
negative men) that MC increases HPV clearance (Level 1b-2b evidence).
If it did increase clearance this may also inflate the impact of the
prevalence benefits mentioned.
3. HPV incidence or acquisition in men: There is no convincing evidence to
suggest that MC decreases HPV acquisition or incident infections in HIV
positive or negative men (Level 1b-2b evidence).
4. HPV in female partners: MC lowers prevalence and incidence in
partners of HIV negative men and improves clearance rates (Level 1b2b).
5. As a public health intervention, it is likely that the effect of HPV
vaccination and behavioral modification will be more effective than
performing universal neonatal circumcisions on all males (Grade B).
3. Circumcision and non-ulcerative STI prevention
The most common non- ulcerative STIs are Gonorrhea, Chlamydia and Trichomonas
infections. Chlamydia is the most commonly diagnosed bacterial STI with approximately
65000 cases reported in Canada in 2006. These STI’s are initiated by bacterial binding to
a variety of host receptors and unlike HIV a biological explanation of how circumcision
can be protective against these infections is lacking.
Two RCTs have addressed the role of MC in these infections. In the Kenyan
study, there was no association between circumcision status and non-ulcerative STIs but
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condom usage was protective (HR 0.64, 95% CI 0.50-0.82) [104]. The Orange Farm
study showed lower Trichomonas vaginalis infection in men only in an as-treated
analysis (Adjusted OR 0.47, 95% CI 0.25-0.92) [105]. A meta-analysis of 30
observational studies failed to identify a statistically significant association between nonulcerative STI’s and MC [106].
In a prospective multi-center, U.S. study involving 2021 men there was evidence
for a statistically non-significant increased prevalence and incidence of gonorrheal
infection in non-circumcised men (odds ratio 1.3, 95%CI 0.9-1.7 and 1.6, 95% CI 1.02.6) but no difference with respect to Chlamydia infection [107]. In another prospective
study, uncircumcised male partners had a higher risk of T vaginalis infection compared to
circumcised partners of T vaginalis infected women (OR 1.8, 95% CI 1.1-3.2) [108].
Mycoplasma genitalium can cause urethritis, cervicitis and pelvic inflammatory disease.
Multivariate analysis of data collected in the Kenyan HIV trial, showed a higher
likelihood of M genitalium infection in non-circumcised men (adjusted OR 0.54, 95% CI
0.29-0.99) [109]. Washing the penis within the first hour after sex had a protective effect.
In a prospective cohort study, circumcision did not seem to have any protective effect on
female partners with regards to chlamydial, gonococcal and trichomonal infections [110].
Recommendations (MC and non-ulcerative STI’s):
1. Currently, there is no significant evidence to support the
protective role of MC in the acquisition of non-HPV, nonulcerative STIs (Level 2a-b evidence, Grade B recommendation).
4. Circumcision and prevention of genital ulcer disease (GUD) and ulcerative STIs
HSV 1 and 2, T pallidum (syphilis), H ducreyi (chancroid) and K granulomatis
(Donovanosis) are the common causes of genital ulcer disease (GUD) with HSV
infections accounting for 70-80% of the infections leading to a genital ulcer [Public
Health Agency of Canada]. The true incidence of HSV 1 and 2 is unknown but these
infections are very common with estimates based on serological tests suggesting at least
20% prevalence in Canada [Public Health Agency of Canada]. Chancroid is extremely
rare in Canada and acquisition is primarily limited to endemic areas. Previously rare in
Canada, the incidence of syphilis has shown an increase especially in MSM males and
sex workers.
Women and men with GUD and HSV-2 have a higher risk of acquiring or
transmitting HIV and conversely HIV infection increases the risk of GUD [111, 112].
Observational studies suggest that prevalent HSV-2 infection leads to a 2-3fold increase
in the risk of HIV acquisition and this risk increases up to 7-fold with incident HSV-2
infection [113, 114]. In a HIV vaccine trial (Step study) conducted in MSM men, HSV-2
infection was an important risk factor for HIV acquisition amongst vaccine and placebo
recipients (HR 2.2, 95% CI 1.4-3.5) [115]. It is likely that the correlation between these
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two infections is due to high-risk sexual behavior making it unclear whether HSV-2
acquisition is an important direct cofactor for HIV infection [116-118].
HSV
Condom usage has a limited role in preventing HSV transmission with a 50% protective
rate for male to female transmission. Unlike HIV, HSV transmission is less dependent
upon the presence of foreskin mucosa.
Level 1-2 evidence
In the Ugandan RCT, which included HIV positive men, Tobian et al showed a lower risk
of HSV 2 seroconversion in the circumcised group over 2-years follow-up (Adjusted IRR
0.70, 95% CI 0.55-0.91) [118]. Consistent condom usage had a slightly higher protective
effect (Adjusted IRR 0.56, 95% CI 0.36-0.89). In a second analysis of the Ugandan RCT
with HIV negative men, the partial protective effect of MC against HSV-2
seroconversion was similar [89]. Multivariate analysis of South African RCT data, did
not show a protective effect for MC against HSV-2 seroincidence (IRR 0.68, 95% CI
0.38-1.22) but the effect was reversed in an as treated analysis presumably due to a 8.2%
crossover rate (IRR 0.45, 95% CI 0.24-0.82) [63].
Mehta et al conducted an RCT in Kenya to assess the protective effect of
circumcision against HIV, HSV-2 and GUD [65]. HSV-2 incidence did not differ by
circumcision status (RR=0.94, 95% CI 0.7-1.25) but HSV-2 incident infection tripled the
risk of HIV acquisition (risk ratio 3.44, 95% CI 1.52-7.80). Moreover, non HSV-GUD
risk was reduced by 50 % in those circumcised (RR 0.52, 95% CI 0.37-0.73). In a
multivariable model, the presence of GUD was associated with a 7 times greater risk of
HIV seroconversion, suggesting that the protective effect of circumcision may be
partially be mediated by reducing the risk of GUD. More than 50% of HIV
seroconversions were preceded by HSV-2 or GUD.
Level 2-4 evidence
In a meta-analysis of observational studies, MC was not associated with a decreased risk
of HSV-2 seropositivity (RR 0.88, 95% CI 0.77-1.01) and this effect was less protective
when restricting the analysis to studies using genital examination rather than self reported
circumcision status (RR 0.97, 95% CI 0.80-1.17) [106]. There was a protective effect of
MC on syphilis seropositivity (RR 0.67, 95% CI 0.54-0.83) though there was significant
heterogeneity amongst the studies and 2 of the largest studies included in this analysis
showed the least protective effects. A definitive conclusion could not be reached for the
risk of chancroid with the adjusted RR varying between 0.13-1.11.
Xu et al estimated the prevalence of circumcision in the US and examined the
association between MC and HSV-2 infection using the National Health and Nutrition
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Examination survey conducted on 6174 men [119]. HSV-2 infection was associated with
age, race and sexual behaviors but not with circumcision status (OR 1.1, 95% CI 0.8-1.5).
Male to male HSV-2 transmission
In an observational study on 3828 men, Jameson et al found that, even in men reporting
primarily an insertive role, MC was not protective against HSV-2 (Adjusted OR 0.66,
95% CI 0.27-1.63) [120]. Barnabas et al conducted a cross sectional study on MSM
males and found that MC was associated with a borderline protective effect against HSV2 infection (OR 0.7, 95% CI 0.5-1.0) [114]. In a Cochrane review of MSM males,
circumcision did not have a protective role in preventing syphilis (OR 0.96, 95% CI 0.821.13) or HSV-2 infections (OR 0.86, 95% CI 0.62-1.2 [77]. In developed countries, the
results of MC can be contradictory, with opposite direction of the effect shown in 2
longitudinal cohort studies from New Zealand [121, 122].
Non-ulcerative and ulcerative STIs in female partners
Gray et al conducted a sub trial in the Ugandan HIV RCT on 1563 HIV negative women
married to men randomized to circumcised and non-circumcised groups followed for a
year [123]. Adjusted analyses suggested a 22% circumcision efficacy for GUD (Adjusted
PRR 0.78, 95% CI 0.61-0.99), a 45% efficacy for trichomonas (Adjusted PRR 0.55, 95%
CI 0.34-0.89) and a weak 18% efficacy for bacterial vaginosis (BV) (Adjusted PRR 0.82,
95% CI 0.74-0.91). In the Ugandan RCT on HIV negative men, MC did not reduce the
risk of HSV-2 acquisition in women partners of both HSV-2 negative and positive male
partners [124]. In addition, in a 2008 prospective study of almost 6000 HIV negative
women showed no difference in female acquisition of Chlamydia (adjusted HR 1.25,
95% CI 0.96-1.63), gonorrhea (adjusted HR 0.99, 95% CI 0.80-1.36) or T. Vaginalis
(adjusted HR 1.05, 95% CI 0.80-1.36) according to circumcision status [110].
Recommendations (MC and ulcerative STI’s):
1. Currently, there is no significant evidence to support the protective role
of universal neonatal circumcision for males and females in the
acquisition of ulcerative STI’s (Level 2-4 evidence, Grade C
recommendation).
2. There is weak evidence of decreased seroconversion for HSV-2 following
MC in adult men in Africa (Level 2a-b).
Circumcision and risk of penile cancer
Epidemiology
Penile cancer is a rare disease with age standardized incidence rates of 0.3-1.0 per
100,000 men in Europe and North America, accounting for 0.4-0.6% of all malignancies
[125]. The potential risk factors for penile cancer include phimosis and balanitis,
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smoking, HPV infections, penile oral sex, Lichen sclerosis, premalignant conditions like
Bowen’s disease and erythroplasia of Queyrat, priapism, urethral stricture and PUVA
therapy [126-128]. Therefore, MC for preventing penile cancer is possibly one of the
several preventive interventions, which still does not account for a host of risk factors
[127-129]. The International Consultation on Urologic Disease 2009 consensus
publication on penile cancer prevention advocated smoking cessation as a Grade C
recommendation while male HPV vaccination and universal circumcision were not
recommended [128].
Biological plausibility
Penile cancer is mediated through 2 mechanisms; HR HPV infections and a subset
through non- HPV mediated mechanisms related to phimosis and Lichen Sclerosus.
Oncogenic HPV (mainly type 16 and 18) prevalence is noted in 40-45% of penile cancers
in several systematic reviews [130-134]. In a Belgian study, HPV DNA was identified in
61% of invasive penile cancer samples with the commonest serotypes being HPV 16, 11,
56 and 18 [134]. Importantly, only 13% of the cases in this study were infected with HPV
types present in HPV vaccines.
Level 2 evidence
In a meta-analysis of 8 studies (7 case control, 1 cross sectional study), Larke et al
showed that circumcision < 18 years of age was protective against invasive penile cancer
with a odds ratio of 0.33 (95% CI 0.13-0.83) [133]. In those circumcised as adults the risk
of invasive carcinoma was increased (OR 2.71, 95% CI 0.93-7.94), presumably because
surgery was performed for conditions predisposing to penile cancer.
Level 3 evidence
In a matched case control study, Tsen et al showed that phimosis was a strong risk factor
for invasive penile cancer (adjusted OR 16, 95% CI 4.5-57) [135]. The protective effect
of neonatal circumcision was not statistically significant when the analysis was restricted
to those who did not have a history of phimosis (OR 0.79, 95% CI 0.29-2.6) and smoking
was a clear identified risk factor (OR 5.9 for > 20 cigarettes/day). In another population
based case control study from Denmark, Madsen et al found that penile cancer was
positively associated with measures of high and early sexual activity, genital warts,
unprotected sex and penile oral sex [136]. Phimosis (OR 4.9, 95% CI 1.85- 13.0), but not
childhood circumcision (p=0.33) was also found to have a strong association on
multivariate analyses. The authors concluded that an unretractable foreskin with HRHPV infection might constitute the single most important risk factor for penile cancer. In
a population based case control study by Daling et al, 137 men with penile cancer were
compared with 671 controls [137]. Lack of childhood circumcision (OR 2.3, 95% CI 1.34.1), phimosis (OR 7.4, 95% CI 3.7-15.0) and cigarette smoking (OR 4.5, 95% CI 2.0-
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10.1) were identified as risk factors for invasive penile cancer but after excluding patients
with phimosis, the analysis did not show a protective effect of childhood circumcision.
Level 2c evidence: Indirect evidence of the role MC in preventing penile cancer can be
investigated by ecological studies in countries with low circumcision rates. Denmark,
with 2% circumcision prevalence, showed decreasing and lower rates of penile cancer
than in the US [138]. However, in a more recent study from Denmark, there was an
increase in the incidence of penile cancer from 1 to 1.3 per 100,000 men-years between
1978 and 2008 [139]. In the US, despite a decrease in circumcision rates, a 1.2% average
annual incidence rate decrease has been noted between 1973 and 2003 [140].
Recommendations (MC and penile cancer):
1. Circumcision decreases the risk of penile cancer (Level 2-3).
2. However, given the low incidence of invasive penile cancer, the partial
protective effect of MC, and the availability of other preventive strategies
like HPV vaccination, condom use and smoking cessation programs, it is
difficult to justify universal neonatal circumcision as a preventive
strategy for preventing penile cancer (Grade B).
3. Recognition and treatment of phimosis during regular health visits is
recommended to decrease the risk of penile cancer (Level 5, Grade D). A
genitourinary exam during puberty is recommended to ensure preputial
retractibility and hygiene, rule out phimosis and counsel regarding HPV
vaccination, safe sexual practices and offer the possibility of circumcision
as a preventive measure against STI’s while specifying the drawbacks
and efficacy of other preventive measures (Grade D).
Circumcision and risk of prostate cancer
A meta- analysis of case control studies by Taylor et al found an increased RR of prostate
cancer in men with a history of STI’s [141]. A recent case control study explored the
association between circumcision and prostate cancer [142]. In a multivariable analysis,
controlling for age, family history, race, history of STI’s, number of partners and history
of prostatitis, the authors did not find an overall association with circumcision (OR 0.87,
95% CI 0.74-1.02). A previous case control study from the UK, looking primarily at
dietary and sexual history found a borderline association on univariate analysis between
circumcision and prostate cancer risk (OR 0.62, 95% CI 0.39-0.98) [143].
Conclusion (MC and prostate cancer)
‒ There is no convincing evidence on the protective effect of MC
against prostate cancer (Level 3- 4 evidence, Grade B).
Role of the foreskin in sensation and sexual function
There is ongoing controversy regarding the impact of circumcision on penile sensitivity
and sexual satisfaction. It is obvious that the foreskin has sensory nerves, which are lost
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following a circumcision. The primary question is whether this presumed loss of
sensation or a possible decrease in glans sensitivity impacts sexual satisfaction in a
measurable and consistent way after accounting for several confounders. The timing of
circumcision (adult versus neonatal) may also impact this effect. The problem is
amplified by the lack of a single objective measure of sensitivity (sensation varying by
type and site assessed, ejaculation latency, arousal). In addition, this effect of MC has to
be studied both from the men and their male and female partners’ perspective. It is hard
to extrapolate results of adult MC studies on sexual function and sensation to neonatal
circumcision.
Adult circumcision
Level 1-2 evidence
A recent meta-analysis included 10 studies with significant heterogeneity and poor
methodological quality to assess the impact of MC on sexual function [144]. There were
no significant differences in sexual desire, dyspareunia, premature ejaculation,
ejaculation latency time or erectile dysfunctions between circumcised and uncircumcised
men. A secondary analysis of the Ugandan RCT showed no long-term differences in
4456 men randomized to immediate and delayed circumcision arms who were assessed at
6, 12 and 24 months for sexual desire, satisfaction and erectile dysfunction [145]. Though
self-reported, there were some significant differences in penetration and pain on
intercourse noted at 6 months favoring uncircumcised men but this difference normalized
over the follow-up period. The trial showed that there was a higher improvement in
sexual satisfaction in the uncircumcised group compared to the circumcised group. In
comparison, another trial from Kenya noted that circumcised men reported increased
penile sensitivity and enhanced ease of reaching orgasm with no sexual dysfunction as
compared to uncircumcised controls [146]. Sexual dysfunction decreased significantly in
both the circumcised and uncircumcised men during follow-up. The 2 trials reported very
different baseline sexual dysfunction and in both the uncircumcised group reported
improvement in sexual satisfaction over time. The Kenyan RCT showed a reduced risk of
any self-reported coital injury in those circumcised compared to uncircumcised men (OR
0.61, 95% CI 0.54-0.68) [147]. There was a significant decrease in reported penile
injuries over follow up even in the control uncircumcised group (decrease from 64% to
43%).
Level 3-4 evidence
In a survey conducted in Denmark, there was no difference in the circumcised and noncircumcised group in current sexual activity but circumcised men were more likely to
report orgasm difficulties (Adjusted OR=3.26, 95% CI 1.05-4.16) [148]. In addition,
women partners with circumcised spouses also noted orgasm difficulties (Adjusted OR=
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2.66, 95% CI 1.07-6.66) and dyspareunia (Adjusted OR 8.45, 95% CI 3.01-23.74).
Another cross-sectional study conducted in Belgium on 1369 men (1059 uncircumcised,
310 circumcised) used a self reported online version of the Self-assessment of Genital
Anatomy, and Sexual Function, Male questionnaire (SAGASF-M) to measure 4
dimensions of sexual function [149]. Overall, for the penis as a whole the 2 groups
differed in sexual pleasure (p=0.044) and discomfort/pain (p=0.018), both favoring the
uncircumcised group. The study concluded that circumcision led to a decrease in glans
sensitivity and overall penile sensitivity. In another detailed study of fine-touch pressure
thresholds in circumcised and uncircumcised men, Sorrells et al noted that the glans of
uncircumcised men had significantly lower pressure thresholds compared to circumcised
men when adjusted for age, type of underwear and ethnicity [150]. Studies before and
after circumcision in the adult population generally do not show any differences in sexual
activity and function, though these studies are often hard to interpret because of the small
sample size, lack of validated instruments to measure sexual function, self reported
outcomes, short follow up times after circumcision and presence of medical indications
for circumcision [151-154]. Intravaginal ejaculation latency time (IELT) was measured in
2 multinational studies using a stopwatch and a blinded timer [155, 156]. The
significance of IELT as a measure of sexual satisfaction and sensation is debatable as a
high IELT may suggest a low sensation and conversely a low IELT may suggest
premature ejaculation and eventual lower sexual satisfaction. Circumcision and condom
use did not impact IELT in both studies.
Neonatal circumcision
A single study compared men circumcised in the neonatal period to uncircumcised men
with normal and abnormal erectile function and used quantitative somatosensory testing
for assessing glans sensation [157]. Circumcised men with or without erectile dysfunction
had worse vibration and better pressure thresholds but these differences disappeared
when controlled for age, hypertension and diabetes.
Sexual function in partners
In an analysis of self reported sexual experience in women partners of men who
participated in the Ugandan RCT before and after circumcision, Kigozi et al showed no
changes in 57% and improved sexual satisfaction in 40% [158]. In 25% of the women
who reported better sexual satisfaction, the reason given was related to the male seeking
more frequent sex. In a study comparing uncircumcised and circumcised homosexual
men as part of the HIM (Health in Men) cohort, Mao et al noted no differences in sexual
difficulties or type of anal sex practiced [159]. Men circumcised after infancy were more
likely to practice receptive anal sex and had a higher incidence of erection difficulties.
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Conclusion
‒ There is lack of any convincing evidence that neonatal
circumcision will impact sexual function or cause a perceptible
change in penile sensation in adulthood (Level 3-4 evidence, Grade
C recommendation).
Medical indications for childhood circumcision
Pathological phimosis
Pathologic phimosis is an uncommon pediatric diagnosis (0.6-1.5% of boys) and is
diagnosed by the presence of a whitish, fibrotic preputial ring [160]. This is different
from physiological phimosis where gentle retraction during examination will show
“flowering” or pouting of the preputial orifice and lack of the cicatricial ring [161-164].
Alternative treatments such as preputioplasty, dorsal slit or steroid therapy can be
attempted, but depending on the severity of the scar tissue, circumcision may be the only
curative option when true phimosis is diagnosed [165-166].
Genital Lichen sclerosis
Genital lichen sclerosis (LS) or balanitis xerotica obliterans is a chronic, inflammatory
dermatosis of the prepuce and glans penis, which can potentially involve the meatus and
urethra. The etiology is unknown and probably multifactorial with a possible autoimmune
or infective etiology [167]. The disease tends to be progressive and older children; those
with obesity and previous surgery tend to have more severe disease [168]. LS should be
suspected when clinical examination reveals a more impressive (than phimosis) thick
white ring like cicatrix at the distal preputial ring, associated with white discoloration and
plaque formation. A history of secondary phimosis in a child with a previously retractile
foreskin and failure of topical steroid therapy is also highly suggestive of LS [168-170].
Overall, the incidence of meatal involvement leading to stenosis is low and estimated to
be around 2 % [169, 170]. Meatal or urethral involvement is more likely with a history of
previous surgery and was seen in 27% in the series by Gargollo et al [168].
The incidence of this condition is underestimated and recent evidence suggests
that in boys referred with a diagnosis of phimosis the incidence ranges between 10-40 %
[169- 172]. In a series of 100 boys referred for phimosis, the incidence of LS was 1.8%
under 6 years of age and up to 21% in those older [171]. In another prospective 10- year
study by Kiss et al, the incidence of histologically confirmed LS was 40%, and 93% of
LS patients had a history of secondary phimosis [170]. In another series of consecutive
patients from the UK, Yardley et al noted a 34% incidence of LS in boys who underwent
circumcision and an overall 12% prevalence of LS in boys referred to a specialist for
foreskin problems [173]. The pathological diagnosis of LS may not correlate with clinical
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suspicion, suggesting circumcision specimen should be routinely subjected to histological
examination to rule out LS [174].
The use of topical steroids in LS is debatable with low response rates and requires
close follow up, because disease progression may lead to glans and urethral involvement
[167, 170, 175]. Circumcision is usually curative, but some children depending on the
degree of involvement may need a meatoplasty, glans resurfacing or urethral
reconstruction [168]. If the meatus is clearly involved a meatoplasty is indicated during
circumcision. However, if the involvement is doubtful close follow up during the postoperative period and uroflowmetry assessments for up to 2 years may be indicated to rule
out stenosis [176]. In addition, secondary to the Koebner phenomenon, recurrent LS may
appear along scar lines of previous surgery and the use of topical steroids is an option in
the post-operative period [167].
Recurrent urinary tract infections
Circumcision can be performed as an adjunct or alternative to prophylactic antibiotics in
infants with UTI-predisposing urological abnormalities as described in the section on
UTIs.
Contraindications of neonatal circumcision
Neonatal circumcision should be performed on medically stable, term infants without
other medical conditions, which require ongoing management or increase risk of surgery.
Routine neonatal circumcision should not be carried out in children with congenital
anomalies of the penis, including hypospadias or epispadias (Fig 4 & 5), ventral
curvature (Fig 6), penoscrotal webbing (Fig 7), and concealed penis (Fig 8). In some of
these conditions, a circumcision can be performed with appropriate technical
modifications but this requires a pediatric urological consult. Prior circumcision may not
compromise distal hypospadias repair in children. In addition, some children with a
hypospadias variant termed megameatus-intact prepuce hypospadias have a normal
foreskin and a distal hypospadias only uncovered during a circumcision. [177]. Most of
these children with this variant or a distal hypospadias can proceed with a circumcision.
However, this requires an ability to recognize the severity of the anomaly and therefore
as a general rule, all boys with hypospadias should ideally not have a circumcision, prior
to a consultation by a pediatric urologist. Children with blood dyscrasias can undergo
circumcision, under appropriate treatment and care [178-179].
Anesthesia for neonatal circumcision
It is clear that neonatal circumcision must be performed with adequate anesthesia and
analgesia [180, 181]. The adverse physiological and behavioral responses of inadequate
pain control in neonates is convincing, can lead to potential complications and alter longterm pain responses in the neonate [180-182]. Different methods used for providing
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anesthesia and/or analgesia during circumcision includes general anesthesia, topical
anesthetics, penile nerve blocks, oral sucrose-glucose administration, non-nutritive
sucking, caudal block and various combinations of the above. In addition, the timing of
neonatal circumcision may impact pain scores, with earlier surgery being beneficial
[183]. Despite a standardized technique, Neonatal/Infant Pain Scores increased
significantly beyond day 8 of life and all neonates beyond 3 weeks of age had a score
indicating pain during the procedure.
There are 3 topical anesthetic options currently available: lidocaine-prilocaine 5%
cream (EMLA), tetracaine 4% gel and liposomal lidocaine 4% cream. When compared to
placebo, crying time was shortened and the heart rate reduced in children who were
circumcised under EMLA [184]. The analgesic effect of EMLA takes almost 60 minutes
to take effect and alone may not be sufficient to control the pain arising from foreskin
removal. Wahlgren et al noted that the depth of penetration is variable with EMLA and
increases with application time to approximately 6 mm after 3-4 hours [185]. Reactions
to EMLA included erythema and blanching. Increased methaemoglobin levels secondary
to oxidation of hemoglobin by prilocaine metabolites, was found to be within normal
limits in two trials of EMLA [185]. Liposomal lidocaine is available in the US and has a
shorter onset of action.
Dorsal penile (DPNB) and ring blocks are effective techniques to manage
circumcision related pain. Based on a RCT that compared these 2 methods with EMLA
for neonatal circumcision, there was no statistical difference in crying time and heart rate
between a ring and dorsal penile nerve block while EMLA was less effective [186]. Two
other trials comparing EMLA to DPNB also demonstrated significantly lower behavioral
distress scores and Neonatal Infant Pain Scale scores in the dorsal nerve block group
[187-188]. Cyna et al did not find a difference between caudal blocks and DPNB in a
meta-analysis of 5 RCT’s comparing these interventions but highlight that the possibility
of a motor block, and requirement of anesthesia expertise makes a caudal block less
preferable in older ambulatory children [189]. Based on the Cochrane review by BradyFryer, a dorsal penile nerve block is the most effective intervention for circumcision
related pain with the caveat that the injection is performed appropriately [180]. A ring
block has similar efficacy and may be easier and safer to use. EMLA cream and other
topical anesthetics are an option when expertise with penile nerve blocks is not available
and ideally should be used in conjunction with a block.
The DPNB is performed by injecting subcutaneously at the 11 and 1 o’clock
positions on the dorsum of the penis close to the base of the penis using a 25- gauge
needle. It is important to aspirate prior to injection to prevent intracorporeal or dorsal
vein injection. A wait time of 5 to 8 minutes is recommended to achieve adequate
anesthesia. Warming the lidocaine or injecting slowly can decrease the pain associated
with injection. In a series of 3909, DPNB the overall complication rate was 0.18% [190].
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Long et al studied the sensory distribution of the penile skin and recommend a ventral
infiltration just proximal to the ventral foreskin incision to add to the dorsal nerve block
[191].
Although it has been shown that analgesic methods such as oral administration of
sucrose, glucose, or parenteral acetaminophen were more effective than placebo, it is
widely accepted that these methods are not sufficient as sole measures for relieving the
pain associated with circumcision [180, 192]. South et al suggested addition of nonnutritive sucking to DPNB based on a RCT, which showed significantly reduced crying
time and salivary cortisol levels [193].
Conclusions for anesthesia and analgesia for neonatal circumcision:
1. A dorsal penile nerve block with a ring block, using proper technique,
is the most effective technique to provide anesthesia during a neonatal
circumcision (Level 1-2 evidence, Grade A recommendation).
2. Topical local anesthetics alone are inferior to nerve and ring blocks
and require an adequate time interval for efficacy and can be used as
an adjunct to penile blocks (Level 1-2 evidence, Grade A
recommendation).
3. Oral sucrose, non- nutritive sucking, music and other environmental
interventions should only be used as an adjunct to these methods
(Level 1-3 evidence, Grade A recommendation).
Complications of circumcision
Neonatal circumcision is a safe surgical procedure that is generally well tolerated.
Circumcision complications can vary depending on the surgeon experience, technique
used, parental expectation of post circumcision appearance, timing of circumcision,
patient anatomic factors, gestational age and the accuracy and degree of reporting. Proper
pre-operative assessment and examination recognizing possible complicating factors
(webbing, ventral skin deficiency, suprapubic fat pad) and adequate post-operative
instructions can prevent the commonest complications.
Neonatal circumcisions are performed in the community by a variety of
practitioners and the complication rate is higher than that for procedures carried out in the
hospital [194]. In addition, it is well documented that physician ability to self-rate success
of a procedure is questionable [195]. When combined with the fact that some of the
complications are delayed (e.g. meatal stenosis), there is a high likelihood that the actual
complication rate for neonatal circumcisions may be underestimated and constitutes an
immense burden to a system where the primary procedure is not covered under universal
healthcare.
According to Pieretti et al, almost 5% of pediatric cases performed at a tertiary
institution in the US over a 5-year span, with an estimated cost of $685,608 were related
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to complications of newborn circumcision [196]. The most frequent complications were
redundant foreskin and meatal stenosis. Kokorowski et al queried the Pediatric Health
Information System database from 28 freestanding pediatric hospitals in the US between
2004-2009 and identified those undergoing revision circumcision, non-newborn primary
circumcision and lysis of penile adhesions following neonatal circumcision [197]. The
study found a 119% increase in the ratio of revision circumcisions to total male
ambulatory procedures during this time period. The median cost for revision circumcision
was $1554 and a total estimated cost of $688,46,31 for the 28 hospitals over 6 years.
Overall complication rates
A recent systematic review on complications of neonatal and infant circumcisions noted a
wide 0 to 16% (median 2%) range of adverse events in 16 prospective studies [198]. The
same review also found that circumcisions performed in older children were associated
with more complications (median 6%) when compared to those carried out in neonates
and infants. A systematic review on safety and efficacy of non-therapeutic MC in 5228
men (15-49 years) showed a 4.8% incidence of complications [199]. The most common
complication was postoperative infection (1.5%), followed by bleeding (1.3%).
Complication rates in the 3 HIV trials conducted in Africa ranged between 1.7-8% [5355].
In 1999, the AAP Task Force on Circumcision reported a complication rate of
0.2-0.6% . In contrast, the Canadian Pediatric Society has published complication rates as
high as 2% for neonatal circumcision [200]. Early complications such as bleeding and
infection occurred in 0.2% of 136086 male infants according to a large review [201]. This
study only included complications entered on inpatient records and does not provide an
estimate of long-term complications. In another US study of 130,475 newborns,
conducted in Washington, US, 0.18% had a bleeding complication after MC [202]. In a
trade off analysis the authors calculated that a complication could be expected in one of
every 476 circumcisions, that 6 UTI’s could be prevented for every complication and
about 2 complications would be expected for every case of penile cancer prevented [203].
A review of complication rates following pediatric circumcision in England between
1997- 2003, showed that 1.2% of boys experienced a short-term complication and
another 0.5% returned to the operating room for a revision within 6 months [3].
Post-circumcision complications can be divided into early and late complications [204211]. Early complications include bleeding, infection, glans necrosis and amputation,
delayed/early slippage of circumcision devices and very rarely death. Late complications
include inadequate skin removal, cosmetic issues, inclusion cysts, adhesions and skin
bridges, suture sinus tracts, ventral curvature, secondary buried penis and phimosis,
urethrocutaneous fistulae and meatal stenosis.
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Factors predicting complication rate
Timing of surgery can be predictive of complications as bleeding related complications
are higher in older infants [212]. Penile adhesions and secondary buried penis is more
likely in infants with a higher weight for length percentile [213]. The results of varying
techniques may also be a possible factor affecting complication rates [209, 214]. Results
from a small RCT, which compared 2 surgical techniques (sleeve vs. Plastibell ®) in
older children, showed that late complications occurred in 12% of the cases that used the
sleeve technique versus 5% with the Plastibell ® device [214]. Current on- going
operator experience was shown to be an important factor in lower bleeding complication
rate compared to patient related variables and long-term operator experience [215].
Penile adhesions, secondary phimosis and concealed penis
These relatively common complications of circumcision are the primary reasons for
reoperation in the late post-operative period following a circumcision. They are more
likely in those with an increased weight for length percentile, a large supra-pubic fat pad
with abnormal dartos attachments to the skin or there is pre-existing peno-scrotal
webbing or ventral penile skin deficiency. Topical steroids and occasional dilatation of
the prepucial ring and retraction can lead to resolution [216, 217]. In children with a
secondary concealed penis, but no phimosis, observation may be an option as the
cosmetic appearance tends to improve with age and surgery should be delayed till the
child is at least 3 years of age [218]. Adhesions of the mucosal collar to the glans are a
common complication and can be prevented by gentle retraction and use of barrier
ointments in the early post- operative period [219].
Meatal stenosis
Meatal stenosis is a common, under-reported complication of circumcision, usually
requiring a ventral meatotomy for correction. It is postulated that chronic irritation of the
meatus, ammoniacal meatitis and/or division of the frenular artery after circumcision may
be predisposing factors. Meatal stenosis can lead to an upwardly deflected urinary stream,
dysuria, urgency or difficulty with voiding and a flat uroflow curve. The incidence of
asymptomatic meatal stenosis (< 5 Fr meatal caliber) can be as high as 20% though its
clinical significance is debatable [208]. In a review of 1009 circumcised boys who were
examined over the age of 3 years of age, Van Howe found an overall 2.8% incidence of
symptomatic meatal stenosis post-neonatal circumcision [207]. Nearly all underwent a
meatotomy but the exact number was unavailable. Studies with long-term follow up of
circumcision report this complication fairly commonly with the incidence varying
between 2.8-11%.
Recommendations:
1. Complication rates post- neonatal circumcision are usually low (around
2%) but given the variability in quoted complication rates and risk of
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delayed complications not treated by the original physician performing
the neonatal circumcision it is likely that the overall complication rate is
slightly higher (Level 2-4).
2. Operator experience and training, recognition of contraindications to
circumcision, technique used, age and patient related variables can
impact results and proper reporting and auditing of results is
recommended [Level 4, Grade D].
Cost analyses of neonatal circumcision
The potential impact of routine neonatal circumcision needs to be studied from an
economic standpoint as currently parent requested circumcision is not covered under
most provincial health plans in Canada. The impact on health service utilization and costs
including direct and indirect procedure costs (costs of managing complications and
circumcision revision, litigation costs and training costs) have to be weighed against
indirect cost savings that may be potentially accrued over time, and balanced against the
costs of implementing other preventive strategies.
Sansom et al performed a cost effectiveness analysis of newborn circumcision on
reducing a US male’s lifetime risk of HIV by applying the results of the African trials.
[220]. The number of circumcisions needed to prevent 1 HIV infection was 298 for all
males, ranging from 65 for black males to 1231 for white males. Newborn circumcision
did not generate cost savings for the white males in the US but was a cost saving
intervention for all males, African-Americans and Hispanics. Schoen et al used a thirdparty US payer database to calculate the cost of newborn circumcision in relation to its
health benefits [221]. Using a high medically indicated need for post-neonatal
circumcision and offsetting costs related to UTI, HIV, balanoposthitis and penile cancer
the total lifetime net cost of a neonatal circumcision was 17 $. The majority of the cost
offset (50%) was by the cost of requiring a post- neonatal period circumcision and not the
actual health benefits of a circumcision. In a contradictory study, by Van Howe, a cost
utility analysis did not show circumcision to be cost effective on sensitivity analysis and
on Monte Carlo simulation [222]. A recent study analyzed the impact of a reducing
circumcision rate in the US on cost implications related to STI’s and UTI [223].
Reducing circumcision rates from 79% to 10% would increase lifetime direct medical
costs by 313$ per foregone circumcision procedure in males.
In a resource rich setting like Canada, with a relatively lower rate of neonatal
circumcisions and an increasing HIV infection risk in MSM, an alternative strategy for
MSM males would be a potential strategy. Anderson et al created a mathematical
transmission model to conduct an economic analysis and considered 4 strategies
(circumcision of all MSM at 18 years of age, all MSM 35-44 years, all insertive MSM >
18 years, all MSM > 18 years) [224]. The model predicted a modest 3-5% decrease in
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HIV infections per year after 25 years of applying these strategies. In the insertive MSM
group, 118 circumcisions would need to be performed to prevent 1 HIV infection. In
countries with a high HIV infection secondary to heterosexual transmission and low
circumcision rates, the cost effectiveness of circumcision is more evident. [225, 226]
Even in this setting, McAllister et al calculated the NNT to prevent 1 HIV infection for
circumcision as 80 and modeling analysis showed that supplying free condoms was 95
times more cost effective than MC [227].
Training implications
Neonatal circumcision is performed by family physicians, obstetricians, pediatricians and
urologists and this leads to non-standard training methods, varying experience during
training and assessment of competency and varying surgical volumes post training.
Several simulated training methods have been described using penile models to allow
standardized teaching using the Mogen and Gomco clamps [228, 229]. In a survey of
obstetric-gynecology residents, 63% planned to perform neonatal circumcisions, but only
44% received formal training to do so [230]. When presented with contraindications to
circumcision like hypospadias, buried penis and micropenis, the average rate of correctly
identified contraindications was a dismal 42%. Evidence from the Ugandan trial data
showed that approximately 100 procedures are needed to gain competence in sleeve
circumcision technique [231]. The rate of moderate or severe adverse events showed a
statistically significant trend decreasing from 8.8% for the first 20 procedures to around
2% beyond 100. Demaria et al stressed the importance of proper training and follow up
and the lack thereof of in the current Canadian health care system with unstructured
training and inability to deal with contraindications and complications of neonatal
circumcision [232].
Summary of results and recommendations
The effect of MC has to be analyzed at the individual and societal level. For the
individual Canadian neonate, there are definite advantages of a circumcision but the exact
estimates of the effect are unknown, the protection provided is not comprehensive, accrue
over a life-time and can be achieved by other preventive health measures (Table 2).
Evidence therefore, must be analyzed based on its quality and applicability and the
GRADE system is an appropriate method to employ when we summarize our results
[233]. There are also clear risks associated with this surgical procedure and parents will
continue to have to weigh the potential benefits and risks of neonatal circumcision. In an
overall societal perspective, given our health care system and the socio-economic and
educational status of our population, universal neonatal circumcision is not justified
based on the evidence available.
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Fig 1. Pathological phimosis.

Fig 2. Balano-posthitis.
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Fig 3. Lichen sclerosus of the foreskin.

Fig 4. Hypospadias .
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Fig 5. Epispadias.

Fig 6. Peno-scrotal webbing.
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Fig 7. Concealed penis.

Fig 8. Ventral curvature.

Fig 9. Megameatus intact prepuce hypospadias variant.
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Table 1. The three randomized trials on circumcision and HIV prevention
Study
(location,
time
period)
Auvert et
al (South
Africa,
2002‒
2005)

Allocation
concealment

Blinding

Inclusion
criteria

n

Followup

Lost to
followup

AEs

Outcomes

ITT RR
(95% CI)

As treated
RR
(95% CI)

Covariate
adjusted
RR

Partial

Study
personnel

Male 18‒24,
wishing to
be
circumcised

3274

251 (8%)
30% in
circumcised
and 33%
uncircumcised

3.8%

Intervention: 20/1546
Control: 49/1582

0.42
(0.25‒0.70)

0.24
(0.14‒0.44)

0.39
(0.23‒0.66)

Bailey et
al (Kenya,
2002‒
2006)

Unclear

HIV testers
Nurses
counselling
and doing
questionnaires
partially
blinded

HIVnegative,
18‒24 years

2784

Stopped at
63% of
total
anticipated
personyears
Stopped at
87%
followup

1.7%

Intervention: 22/1388
Control: 47/1392

0.47
(0.28‒0.78)

0.45
(0.27‒0.76)

0.44‒0.47

Gray et al
(Uganda
2002‒
2006)

Partial

None specified

HIVnegative,
15‒49 years

4996

86% (1501)
completed 24
month
followup,
overall
1283/2784
(46%) did not
complete trial
22% at 24
months
followup

8%

Intervention: 22/2387
Control: 45/2430

0.49
(0.28‒0.84)

0.45
(0.25‒0.78)

0.49
(0.29‒0.81)

Stopped at
72%
persontime
accrual
AE: adverse events; CI: confidence interval; ITT: intention-to-treat; RR: relative risk.
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Table 2. Benefits of circumcision classified by GRADE recommendations
Clinical
Direction of
Amount of
Level of
GRADE
benefit
evidence
effect
evidence
quality of
evidence
Decreased
Positive
0.07‒0.23
Level 2
Low quality
risk of UTI
Decreased
Positive
0.34‒0.62
Level 1
High quality
risk of HIV
Decreased
Positive
0.57‒ 0.77
Level 1
Moderate
risk of HPV
quality
prevalence
Decreased
Unclear
NS
Level 2
Low quality
risk of HPV
incidence
Decreased
Positive
0.36‒0.91
Level 2
Moderate
risk of HSV
quality
Decreased
Positive
0.13‒0.83
Level 2
Low quality
risk of penile
cancer
*
Concerns related to external validity of data for Canadian population. HPV: human
papilloma virus; HSV: herpes simplex virus; UTI: urinary tract infection.

GRADE
strength of
recommendation
Weak
Strong*

Weak

Weak

Weak
Weak
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Table 3. Summary results for level 1-2 evidence benefits of circumcision classified by GRADE
recommendations
Clinical
Direction of
Amount of
Level of
GRADE
GRADE
benefit
evidence
effect
evidence
quality of
strength of
evidence
recommendation
Decreased
Positive
0.07-0.23
Level 2
Low quality
Weak
risk of UTI
Decreased
Positive
0.34-0.62
Level 1
Strong*
High quality
risk of HIV
Decreased
Positive
0.57- 0.77
Level 1
Moderate
Weak
risk of HPV
Prevalence
quality
prevalence
rate ratio
Decreased
Unclear
NS
Level 2
Low quality
Weak
risk of HPV
incidence
Decreased
Positive
0.36-0.91
Level 2
Moderate
Weak
risk of HSV
quality
Weak
Positive
0.13-0.83
Low quality
Decreased
Level 2
risk of
penile
cancer
*

Uncertainty related to: 1) effects of neonatal circumcision in Canadian setting; 2)
whether circumcision represents a wise use of resources compared to other preventive
strategies; 3) the balance of advantages versus risks of circumcision given the uncertainty
of circumcision risks. HPV: human papilloma virus; HSV: herpes simplex virus; UTI:
urinary tract infection.

